MOTIF BIO PLC/S (NASDAQ:MTFB)’s stock price was down 11.5% during mid-day trading on Monday . The company traded as low as $0.22 and last traded at $0.23, approximately 1,473,401 shares were traded during trading. An increase of 349% from the average daily volume of 327,934 shares. The stock had previously closed at $0.26.

A number of research analysts have recently issued reports on MTFB shares. Zacks Investment Research raised MOTIF BIO PLC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. ValuEngine raised MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Northland Securities set a $5.00 target price on MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Monday, July 15th.

The company has a market capitalization of $3.20 million, a P/E ratio of -3.08 and a beta of -0.01. The company has a 50 day moving average of $0.55 and a 200-day moving average of $1.17.

A hedge fund recently raised its stake in MOTIF BIO PLC/S stock. Susquehanna International Group LLP increased its position in MOTIF BIO PLC/S (NASDAQ:MTFB) by 207.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,657 shares of the company’s stock after buying an additional 26,740 shares during the period. Susquehanna International Group LLP owned 0.27% of MOTIF BIO PLC/S worth $26,000 at the end of the most recent reporting period. Institutional investors own 9.58% of the company’s stock.


Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

See Also: Is the QQQ ETF safe?

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with's FREE daily email newsletter.